Related Experiment Videos
Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and
Jun-ichi Kadota1, Hiroshi Mukae, Takeshi Fujii
1Division of Pathogenesis and Disease Control, Department of Infectious Diseases, Oita University Faculty of Medicine, Oita, Japan. kadota@med.oita-u.ac.jp
Chest
|April 14, 2004
Summary
Human T-cell lymphotropic virus type 1 (HTLV-1)-associated bronchiolitis and diffuse panbronchiolitis share similarities but differ in treatment response and T-cell activation. HTLV-1 bronchiolitis may be a distinct condition from diffuse panbronchiolitis.
Area of Science:
- Pulmonology
- Infectious Diseases
- Immunology
Background:
- Human T-cell lymphotropic virus type 1 (HTLV-1)-associated bronchiolitis and diffuse panbronchiolitis (DPB) exhibit overlapping clinical presentations.
- Differentiating these conditions is crucial for appropriate patient management and understanding disease pathogenesis.
Purpose of the Study:
- To compare the clinical features of HTLV-1-associated bronchiolitis and DPB.
- To evaluate the impact of long-term macrolide treatment on both conditions.
- To investigate the role of T-cell activation, specifically Interleukin-2 receptor (IL-2R) expression, in differentiating these pulmonary diseases.
Main Methods:
- A comparative study involving 58 Japanese patients: 15 with HTLV-1-associated bronchiolitis and 43 with DPB.
- Clinical, radiologic (CT scans), and BAL fluid analyses were performed.
- Pulmonary function (FEV1), blood gas levels (PaO2), and cold hemagglutinin (CHA) levels were assessed pre- and post-macrolide treatment.
- IL-2R expression on T cells in BAL fluid was analyzed via flow cytometry.
Main Results:
- Clinicopathologic features, including CT findings and BAL fluid analysis, were similar between the two groups.
- Patients with HTLV-1-associated bronchiolitis showed a higher ratio of IL-2R-positive cells in BAL fluid compared to DPB patients.
- Macrolide treatment demonstrated a lesser improvement in PaO2, FEV1, and CHA in HTLV-1-associated bronchiolitis patients, with non-responders exhibiting high IL-2R levels.
Conclusions:
- The similar clinicopathologic features suggest DPB could be a pulmonary manifestation of HTLV-1 infection.
- Distinct responses to macrolide therapy and differing levels of activated T cells (IL-2R+) indicate HTLV-1-associated bronchiolitis may represent a separate entity from DPB.
- These findings highlight the importance of IL-2R expression and treatment response in distinguishing between these two bronchiolar diseases.